Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

 

not be extended beyond the period of time that would enable the stock option to remain exempt under IRS Regulation 409A.

 

4.                                      Section 21. Miscellaneous. The last sentence of such section is hereby deleted and replaced with the following:

 

This is a Massachusetts contract and shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the conflict of laws principles thereof.

 

This Amendment sets forth the entire amendment and modification to the Agreement intended by the parties. Further, this Amendment and the Agreement constitute the entire agreement and understanding of the parties relating to the subject matter contained therein. The amendments and modifications to the Agreement are specifically limited to the terms and conditions discussed herein. The remainder of the terms and conditions of the Agreement, as agreed to by the parties, remains in full force and effect.

 

THIS AMENDMENT IS EXECUTED by the parties as of the date first written above.

 

Proteon Therapeutics, Inc. (“Company”):

 

/s/ Brendan O’Leary

 

Brendan O’Leary

 

Chairman, Compensation Committee of the Board of Directors

 

 

 

Date:

6/30/09

 

 

 

Timothy P. Noyes

 

 

 

/s/ Timothy P. Noyes

 

Timothy P. Noyes

 

President and CEO

 

 

 

Date:

6-22-09